Go online to PeerView.com/MJJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, developed in collaboration with the Bladder Cancer Advocacy Network, a panel of leading bladder cancer experts pair important analyses of the latest evidence on a new generation of therapeutics with practical insights that can be used to guide decision-making in the clinic. The panel also provides guidance on how to manage several challenging patient types across the disease spectrum—from locally advanced metastatic to non-muscle–invasive bladder cancer. Upon completion of this activity, participants should be better able to: Review the rationale for the use of and latest evidence on approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, FGFR inhibitors, and gene therapy, throughout the bladder cancer disease continuum, Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer, Optimally apply new and emerging treatment approaches for the management of bladder cancer while considering the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer, Recommend current and ongoing clinical trials that incorporate checkpoint blockade, novel targeted approaches, and gene therapy to eligible patients across disease settings in bladder cancer